Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer

Clinical Cancer Research

Volumn 11, Issue 24, 2005, Pages 8722-8727

  Hutson, Paul R ^a,b   Love, Richard R ^d   Havighurst, Thomas C ^c   Rogers, Eric ^b   Cleary, James F ^b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; ESTRONE; ESTRONE SULFATE; EXEMESTANE; LETROZOLE; NORTAMOXIFEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ENZYME INACTIVATION; ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MODEL;

ADULT; AGED; ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DRUG INTERACTIONS; ESTRADIOL; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN;

EID: 29344456141     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0915     Document Type: Article

References (46)

1. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29.
2. Dellapasqua S, Castiglione-Gertsch M.The choice of systemic adjuvant therapy in receptor-positive early breast cancer. Eur J Cancer 2005;41:357-64.
3. Chakravarti S, Collins WP, Newton JR, Oram DH, Studd JW. Endocrine changes and symptomatology after oophorectomy in premenopausal women. Br J Obstet Gynaecol 1977;84:769-75.
4. Freedman AN, Graubard BI, Rao SR, McCaskill-Stevens W, Ballard-Barbash R, Gail MH. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst 2003;95:526-32.
5. Martino S, Costantino J, McNabb M, et al. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. Oncologist 2004;9:116-25.
6. Buzdar AU, Robertson JF, Eiermann W, Nabholtz JM. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane. Cancer 2002; 95:2006-16.
7. Njar VC, Brodie AM. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999;58:233-55.
8. Boeddinghaus IM, Dowsett M. Comparative clinical pharmacology and pharmacokinetic interactions of aromatase inhibitors. J Steroid Biochem Mol Biol 2001;79:85-91.
9. Scott LJ, Wiseman LR. Exemestane. Drugs 1999;58: 675-80.
10. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33:1767-73.
11. Paridaens R, Dirix L, Beex L, et al. Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control. Clin Breast Cancer 2000;1:S19-21.
12. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study. Clin Breast Cancer 2000;1:S15-8.
13. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18: 1399-411.
14. Paridaens R, Dirix L, Lohrisch C, et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 2003;14:1391-8.
15. Zaccheo T, Giudici D, Lombardi P, di Salle E. A new irreversible aromatase inhibitor, 6-methylenandrosta-1,4-diene-3,17-dione (FCE 24304): antitumor activity and endocrine effects in rats with DMBA-induced mammary tumors. Cancer Chemother Pharmacol 1989;23:47-50.
16. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
17. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
18. Scherr D, Swindle PW, Scardino PT National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003;61:14-24.
19. Jelovac D, Macedo L, Handratta V, et al. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin Cancer Res 2004;10: 7375-81.
20. Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the "Arimidex and tamoxifen alone or in combination" (ATAC) trial. Br J Cancer 2001;85: 317-24.
21. Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338-43.
22. Dowsett M, Tobias JS, Howell A, et al. The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999;79:311-5.
23. Rivera E, Valero V, Francis D, et al. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 2004;10:1943-8.
24. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10.
25. Love RR, Hutson PR, Havighurst TC, Cleary JF. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer. Clinical Cancer Research 2005;11:1500-3.
26. Johnson MD, Zuo H, Lee KH, et al. Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004;85:151-9.
27. Cenacchi V, Baratte S, Cicioni P, Frigerio E, Long J, James C. LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Pharm Biomed Anal 2000;22:451-60.
28. Johannessen DC, Engan T, Di Salle E, et al. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 1997;3:1101-8.
29. Gibaldi M, Perrier D. Pharmacokinetics. 1st ed. New York: Marcel Dekker; 1975.
30. Anonymous. Statistical Approaches to Establishing Bioequivalence. Rockville: U.S. Food and Drug Administration, CDER; 2001.
31. Beal SL, Sheiner LB. NONMEM users guides. Hanover: GloboMax LLC; 1989-98.
32. Parke J, Holford NHG, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999;59:19-29.
33. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
34. Wong ZW, Ellis MJ. First-line endocrine treatment of breast cancer: aromatase inhibitor or antioestrogen? Br J Cancer 2004;90:20-5.
35. Herrlinger C, Braunfels M, Fink E, et al. Pharmacokinetics and bioavailability of tamoxifen in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992;30: 487-9.
36. Wilkinson P, Ribeiro G, Adam H, Patterson J. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer. Cancer Chemother Pharmacol 1980;5:109-11.
37. Kemp JV, Adam HK, Wakeling AE, Slater R. Identification and biological activity of tamoxifen metabolites in human serum. Biochem Pharmacol 1983;32: 2045-52.
38. Lien EA, Solheim E, Ueland PM. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res 1991;51: 4837-44.
39. Soininen K, Kelimola T, Elomaa I, Salmo M, Pissanen P. The steady-state pharmacokinetics of tamoxifen and it metabolites in breast cancer patients. J Int Med Res 1986;14:162-5.
40. Fuchs WS, Leary WP, van der Meer MJ, Gay S, Witschital K, von Nieciecki A. Pharmacokinetics and bioavailability of tamoxifen in postmenopausal healthy women. Arzneimittelforschung 1996;46:418-22.
41. Crewe HK, Ellis SW, Lennard MS, Tucker GT. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997; 53:171-8.
42. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003;42:361-72.
43. Lien EA, Solheim E, Kvinnsland S, Ueland PM. Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of tamoxifen in human bile. Cancer Res 1988;48:2304-8.
44. Anonymous. AROMASIN prescribing information. Pfizer-Pharmacia; 2005.
45. Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, Buchan P. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 2004;53:475-81.
46. Mauras N, Lima J, Patel D, et al. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 2003;88:5951-6.